EDMONTON, ALBERTA--(Marketwire - Sept. 10, 2008) - CV Technologies Inc. (TSX:CVQ) today announced preliminary results suggesting that COLD-FX® affects the human immune system by targeting the adaptive pathway, which is the immunity developed throughout life. This result was obtained through a randomized, double-blind, placebo-controlled trial of the Company’s lead product and Canada’s number one selling cold and flu remedy, COLD-FX, demonstrating its immune-modulating effects in front-line healthcare workers at New Jersey’s prestigious Hackensack University Medical Center (HUMC).
